Note: This document contains side effect information about risedronate. Some of the dosage forms listed on this page may not apply to the brand name Actonel.
Common side effects of Actonel include: abdominal pain, arthralgia, and ostealgia. Other side effects include: bone fracture, arthropathy, and myalgia. See below for a comprehensive list of adverse effects.
Applies to risedronate: oral tablet, oral tablet delayed release
Along with its needed effects, risedronate (the active ingredient contained in Actonel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking risedronate:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking risedronate:
Symptoms of overdose
Some side effects of risedronate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to risedronate: oral delayed release tablet, oral tablet
Abdominal and musculoskeletal pain were commonly reported adverse effects.
Very common (10% or more): Hypertension (up to 10.5%)
Common (1% to 10%): Arrhythmia (2%) in men with osteoporosis
Frequency not reported: Syncope, vasodilation
Very common (10% or more): Constipation (up to 12.9%), diarrhea (up to 10.8%), dyspepsia (up to 10.8%), nausea (up to 10.5%)
Common (1% to 10%): Abdominal pain, vomiting, abdominal upper pain, gastritis, gastroesophageal reflux disease, gastroenteritis
Uncommon (0.1% to 1%): Duodenitis, glossitis
Rare (less than 0.1%): Esophageal stricture
Postmarketing reports: Esophagitis, esophageal or gastric ulcers
Very common (10% or more): Urinary tract infection (up to 11.1%)
Common (1% to 10%): Nocturia (1.6%), cystitis, hemorrhoids, Hiatus hernia, urinary disorders, reproductive system and breast disorders
Very common (10% or more): Arthralgia (up to 23.7%)
Common (1% to 10%): Back pain, pain in extremity, musculoskeletal pain, bone pain, muscle spasms, myalgia, neck pain, arthritis, traumatic bone fracture, join disorder, leg cramps, myasthenia (1.6%), osteoarthritis, tendonitis
Rare (less than 0.1%): Severe or incapacitating bone, join, or muscle pain; osteonecrosis of the jaw (ONJ); atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)
Frequency not reported: Muscle spasms
Very common (10% or more): Accidental injury (up to 16.9%), pain (up to 14.1%), flu syndrome (up to 11.6%)
Common (1% to 10%): Tinnitus (1.6%), asthenia, peripheral edema, contusion, herpes zoster (1% to 2.6%), ear and labyrinth disorders, vertigo
Very common (10% or more): Bronchitis (up to 10%)
Common (1% to 10%): Influenza, upper respiratory infection, chest pain, sinusitis, rhinitis, pharyngitis, increased cough, apnea (1.6%)
Postmarketing reports: Asthma exacerbations
Common (1% to 10%): Rash
Frequency not reported: Pruritus
Common (1% to 10%): Elevated levels of parathyroid hormone (PTH), endocrine disorders
Common (1% to 10%): Anemia (1% to 2.6%), blood and lymphatic system disorders
In most of the postmarketing reported cases the patients were also treated with other products known to cause hepatic disorders.
Common (1% to 10%): Colitis (1.6%), hepatobiliary disorders
Rare (less than 0.1%): Abnormal liver function test
Postmarketing reports: Serious hepatic disorders
Common (1% to 10%): Allergic reactions
Postmarketing reports: Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, anaphylactic reactions
Common (1% to 10%): Immune system disorders
Common (1% to 10%): Decreased weight, hypocalcemia (1.6%), transient decreases from baseline of serum calcium and phosphate, hypercholesterolemia
Transient decreases from baseline in serum calcium (less than 1%) and serum phosphate (less than 3%) were observed within 6 months in patients in osteoporosis clinical trials treated with doses of 5 mg daily immediate-release.
Common (1% to 10%): Dizziness, headache, insomnia, sciatica (0.6% to 2.3%)
Common (1% to 10%): Cataract; amblyopia, corneal lesion and dry eye (1.6%)
Uncommon (0.1% to 1%): Iritis
Rare (less than 0.1%): Eye inflammation including uveitis
Common (1% to 10%): Benign prostatic hyperplasia (5%) in men with osteoporosis; neoplasms benign, malignant and unspecified (including cysts and polyps)
Common (1% to 10%): Depression, psychiatric disorders
Common (1% to 10%): Nephrolithiasis (3%) in men with osteoporosis, renal disorders
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Actonel